Search Results - "F. Peyvandi"

Advances in the treatment of bleeding disorders by Peyvandi, F., Garagiola, I., Biguzzi, E.

“…Summary Historically, the bleeding episodes in subjects with coagulation disorders were treated with substitution therapy, initially with whole blood and fresh…”
Get full text

A critical appraisal of one‐stage and chromogenic assays of factor VIII activity by Peyvandi, F., Oldenburg, J., Friedman, K. D.

“…Summary Accurate and precise potency determination by manufacturers of different types of factor VIII product (plasma‐derived and recombinant FVIII [rFVIII])…”
Get full text

Factor XIII deficiency diagnosis: Challenges and tools by Karimi, M., Peyvandi, F., Naderi, M., Shapiro, A.

“…Factor XIII deficiency (FXIIID) is a rare hereditary bleeding disorder arising from heterogeneous mutations, which can lead to life‐threatening hemorrhage. The…”
Get full text

Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies by Scully, M., Cataland, S., Coppo, P., Rubia, J., Friedman, K. D., Kremer Hovinga, J., Lämmle, B., Matsumoto, M., Pavenski, K., Sadler, E., Sarode, R., Wu, H., Gale, D., Fujimura, Y., McDonald, V., Peyvandi, F., Scharrer, I., Veyradier, A., Westwood, J. P.

“…Essentials An international collaboration provides a consensus for clinical definitions. This concerns thrombotic microangiopathies and thrombotic…”
Get full text

Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders by PEYVANDI, F., PALLA, R., MENEGATTI, M., SIBONI, S. M., HALIMEH, S., FAESER, B., PERGANTOU, H., PLATOKOUKI, H., GIANGRANDE, P., PEERLINCK, K., CELKAN, T., OZDEMIR, N., BIDLINGMAIER, C., INGERSLEV, J., GIANSILY‐BLAIZOT, M., SCHVED, J. F., GILMORE, R., GADISSEUR, A., BENEDIK‐DOLNIČAR, M., KITANOVSKI, L., MIKOVIC, D., MUSALLAM, K. M., ROSENDAAL, F. R.

“…Background:  The European Network of Rare Bleeding Disorders (EN‐RBD) was established to bridge the gap between knowledge and practise in the care of patients…”
Get full text

Future of coagulation factor replacement therapy by Peyvandi, F., Garagiola, I., Seregni, S.

“…Summary Over a million patients worldwide currently suffer from hemophilia and other congenital clotting factor deficiencies. Patients affected with hemophilia…”
Get full text

Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency by James, P., Salomon, O., Mikovic, D., Peyvandi, F.

“…Summary Rare bleeding disorders (RBDs) are inherited deficiencies of coagulation factors such as fibrinogen, factor (F) II, FV, FVII, combined FV+FVIII, FX,…”
Get full text

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura by Peyvandi, F., Scully, M., Kremer Hovinga, J. A., Knöbl, P., Cataland, S., De Beuf, K., Callewaert, F., De Winter, H., Zeldin, R. K.

“…Essentials Acquired thrombotic thrombocytopenic purpura (aTTP) is linked with significant morbidity/mortality. Caplacizumab's effect on major thromboembolic…”
Get full text

Molecular diagnosis of von Willebrand disease by Baronciani, L., Goodeve, A., Peyvandi, F.

“…The role of molecular characterization in the diagnosis of von Willebrand disease (VWD) is not essential if the patients have been extensively investigated…”
Get full text

Evolution of Haemophilia Care in Europe: 10 years of the principles of care by Noone, D, O'Mahony, B, Peyvandi, F, Makris, M, Bok, A

“…Abstract Introduction The European principles of care in haemophilia marked their first decade in 2018. These guiding principles were the beginning of the…”
Get full text

Fibrinogen replacement therapy for congenital fibrinogen deficiency by BORNIKOVA, L., PEYVANDI, F., ALLEN, G., BERNSTEIN, J., MANCO‐JOHNSON, M. J.

“…This review of published studies was conducted to derive data on patients with congenital fibrinogen deficiency (CFD), including dosing of fibrinogen…”
Get full text

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery by Peyvandi, F., Mamaev, A., Wang, J.‐D., Stasyshyn, O., Timofeeva, M., Curry, N., Cid, A. R., Yee, T. T., Kavakli, K., Castaman, G., Sytkowski, A.

“…Summary Essentials Recombinant von Willebrand factor (rVWF) is effective in von Willebrand disease (VWD). A phase 3 study of rVWF, with/without recombinant…”
Get full text

SIPPET: methodology, analysis and generalizability by Peyvandi, F., Mannucci, P. M., Palla, R., Rosendaal, F. R.

“…The development of anti‐FVIII neutralizing alloantibodies (inhibitors), occurring in about one‐third of previously untreated patients (PUPs) with severe…”
Get full text

Gynecological and obstetrical manifestations of inherited bleeding disorders in women by PEYVANDI, F., GARAGIOLA, I., MENEGATTI, M.

“…Patients affected by bleeding disorders present a wide spectrum of clinical symptoms that vary from a mild or moderate bleeding tendency to significant…”
Get full text

Plasma ADAMTS‐13 levels and the risk of myocardial infarction: an individual patient data meta‐analysis by Maino, A., Siegerink, B., Lotta, L. A., Crawley, J. T. B., Cessie, S., Leebeek, F. W. G., Lane, D. A., Lowe, G. D. O., Peyvandi, F., Rosendaal, F. R.

“…Summary Background Low ADAMTS‐13 levels have been repeatedly associated with an increased risk of ischemic stroke, but results concerning the risk of…”
Get full text

Reduced circulating FABP2 in patients with moderate to severe COVID-19 may indicate enterocyte functional change rather than cell death by Assante, G., Tourna, A., Carpani, R., Ferrari, F., Prati, D., Peyvandi, F., Blasi, F., Bandera, A., Le Guennec, A., Chokshi, S., Patel, V. C., Cox, I. J., Valenti, L., Youngson, N. A.

“…The gut is of importance in the pathology of COVID-19 both as a route of infection, and gut dysfunction influencing the severity of disease. Systemic changes…”
Get full text

Inhibitor development in haemophilia by Peyvandi, F., Makris, M.

Get full text

Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity by PEYVANDI, F., DI MICHELE, D., BOLTON‐MAGGS, P. H. B., LEE, C. A., TRIPODI, A., SRIVASTAVA, A.

Get full text

Minimal factor XIII activity level to prevent major spontaneous bleeds: reply by Menegatti, M., Palla, R., Bucciarelli, P., Peyvandi, F.

Get full text

Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis by Peyvandi, F., Cannavò, A., Garagiola, I., Palla, R., Mannucci, P. M., Rosendaal, F. R., El‐Beshlawy, A., Elalfy, M., Ramanan, V., Eshghi, P., Hanagavadi, S., Varadarajan, R., Karimi, M., Manglani, M. V., Ross, C., Young, G., Seth, T., Apte, S., Nayak, D. M., Santagostino, E., Elisa Mancuso, M., Sandoval Gonzalez, A. C., Mahlangu, J. N., Bonanad Boix, S., Cerqueira, M., Ewing, N. P., Male, C., Owaidah, T., Soto Arellano, V., Kobrinsky, N. L., Majumdar, S., Perez Garrido, R., Sachdeva, A., Simpson, M., Thomas, M., Zanon, E., Antmen, B., Kavakl, K., Manco‐Johnson, M. J., Martinez, M., Marzouka, E., Mazzucconi, M. G., Neme, D., Palomo Bravo, A., Paredes Aguilera, R., Prezotti, A., Schmitt, K., Wicklund, B. M., Zulfikar, B.

“…Essentials Recombinant factor VIII (rFVIII) was contrasted with plasma‐derived FVIII (pdFVIII). In previously untreated patients with hemophilia A, rFVIII led…”
Get full text